Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2025 04:05 ET | Source: Castle Biosciences, Inc.

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

Castle is presenting data on DecisionDx®-Melanoma and its pipeline atopic dermatitis (AD) test at the 25th Annual Fall Clinical Dermatology Conference.
October 14, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

New York, USA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight The melanoma market...
October 08, 2025 05:12 ET | Source: Research and Markets

Cutaneous Squamous Cell Carcinoma Market Forecast Report 2025-2035, with Focus on Regeneron Pharmaceuticals, Sanofi, Merck & Co., Checkpoint Therapeutics, Incyte, and Sirnaomics

Dublin, Oct. 08, 2025 (GLOBE NEWSWIRE) -- The "Cutaneous Squamous Cell Carcinoma Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has...
September 25, 2025 00:08 ET | Source: Immuneering Corporation

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A
September 24, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Placement to Sanofi
September 24, 2025 16:01 ET | Source: Immuneering Corporation

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
September 22, 2025 09:35 ET | Source: Research and Markets

BRAF Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast 2015-2036

Dublin, Sept. 22, 2025 (GLOBE NEWSWIRE) -- The "BRAF Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036" report has been added to ResearchAndMarkets.com's...
September 10, 2025 07:00 ET | Source: Immuneering Corporation

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Septe
August 26, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering Announces Closing of $25 Million Private Placement

Immuneering Announces Closing of $25 Million Private Placement
August 26, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Untreated Metastatic or Unresectable Melanoma Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight

New York, USA, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Untreated Metastatic or Unresectable Melanoma Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in Oncology Therapeutics Space |...